Il-5-inhibiting monoclonal antibodies, such as mepolizumab, have been approved by the FDA for eosinophilic asthma, as an add-on treatment for severe asthma, and for adult patients with eosinophilic granulomatosis with polyangiitis [14]. The gene discussed is IL5; the disease is asthma.